Longevity & AgingGLP-1 Drugs Cut Obesity-Related Cancer Risk by 41% in Landmark Study
A large propensity-matched study published in Annals of Oncology found that people taking GLP-1 receptor agonists like semaglutide or tirzepatide for weight loss had a 41% lower risk of developing obesity-related cancers compared to those using diet or exercise alone. Researchers analyzed data from the TriNetX clinical database covering patients from 2014 to 2025, focusing exclusively on obese, non-diabetic individuals. The risk reduction exceeded 50% for multiple myeloma, pancreatic, endometrial, and colorectal cancers. Notably, tirzepatide users saw a 69% reduction in cancer risk versus only 20% for semaglutide users. This is the first study to isolate GLP-1 effects specifically in people taking the drugs for weight loss rather than diabetes management.
